Please login to the form below
tenofovir alafenamide
This page shows the latest tenofovir alafenamide news and features for those working in and with pharma, biotech and healthcare.
ViiV takes on Gilead’s PReP dominance with HIV injectable data
emtricitabine/tenofovir disoproxil fumarate). ... Gilead is trying to position its recently-approved two-drug combination Descovy (emtricitabine/tenofovir alafenamide) as a successor to Truvada that is safer, with significant improvements on measures of
Latest news
-
GSK considers more divestments to help R&D push
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.
-
Gilead builds case for Descovy PrEP after FDA approval
Descovy (emtricitabine/tenofovir alafenamide) claimed its FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green
-
J&J pledges $500m investment into HIV and tuberculosis R&D
and tenofovir alafenamide) was recently approved by the FDA.
-
Gilead claims FDA okay for Descovy as second PrEP option
Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing
-
ViiV builds case for switching to its two-drug HIV combinations
48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing
More from news
Approximately 4 fully matching, plus 42 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
Page & Page
For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
